ERBB2 and neoplasm: According to tumor phenotypes, ITC, micro-metastases, and macro-metastases rates were respectively 5.5% (75/1354), 27.5% (373/1354), and 66.9% (906/1354) among patients with ER-positive/HER2-negative tumors, 6.67% (9/135), 27.4% (37/135), and 65.9% (89/135) among patients with ER-positive/HER2-positive tumors, 7.3% (3/41), 24.4% (10/41), and 68.3% (28/41) among patients with ER-negative/HER2-positive tumors, and 8.2% (8/97), 29.9% (29/97), and 61.8% (60/97) among patients with triple-negative tumors.